9 completed, 2 terminated, 1 recruiting. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Recruiting 1 |
| Phase 2 | 5 | Completed 3, Terminated 2 |
Follow Enyo Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions EYP651/Vonafexor low dose, EYP651/Vonafexor high dose, EYP651/CYP3A4 inhibitor - Healthy Adult Male and Female Volunteers | Phase 1 | Recruiting | Enyo Pharma | 40 | 2025-10-28 | 2026-02-27 |
| Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) Vonafexor low dose, Vonafexor high dose - Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3 | Phase 2 | Terminated | Enyo Pharma | 10 | 2025-07-01 | 2026-04-23 |
| Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) Vonafexor - Alport Syndrome | Phase 2 | Completed | Enyo Pharma | 26 | 2024-08-01 | 2026-02-09 |
| A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir EYP001a, Entecavir, Pegylated interferon alpha2a - Hepatitis B, Chronic | Phase 2 | Completed | Enyo Pharma | 20 | 2020-05-25 | 2022-08-25 |
| Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD) EYP001a, Placebo, Nucleotide analogue (Entecavir or Tenofovir Disoproxil) - Hepatitis B, Chronic | Phase 2 | Terminated | Enyo Pharma | 26 | 2020-05-12 | 2022-11-02 |
| Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose [14C]-EYP001a - Healthy | Phase 1 | Completed | Enyo Pharma | 6 | 2019-07-24 | 2019-09-11 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients EYP001a - NASH - Nonalcoholic Steatohepatitis, Healthy | Phase 1 | Completed | Enyo Pharma | 16 | 2019-06-11 | 2020-09-25 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH) Vonafexor, Placebo - Non-alcoholic Steatohepatitis | Phase 2 | Completed | Enyo Pharma | 120 | 2019-01-30 | 2023-05-06 |
| Drug Drug Interaction Study for EYP001 With Entecavir EYP001, Entecavir 1 MG - Hepatitis B, Chronic | Phase 1 | Completed | Enyo Pharma | 16 | 2018-02-12 | 2018-07-26 |
| Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects EYP001a, Placebo, Entecavir - Hepatitis B, Chronic | Phase 1 | Completed | Enyo Pharma | 73 | 2017-09-21 | 2018-08-21 |
| EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection EYP001a - Hepatitis B, Chronic | Phase 1 | Completed | Enyo Pharma | 11 | 2017-02-10 | 2018-03-05 |
| Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects EYP001a, Placebo - Healthy | Phase 1 | Completed | Enyo Pharma | 80 | 2016-08-01 | 2017-04-13 |
Hepatitis B, Chronic (5) · Non-alcoholic Fatty Liver Disease (2) · Liver Diseases (1) · Nephritis, Hereditary (1) · Renal Insufficiency, Chronic (1)
entecavir (4) · peginterferon alfa-2a (2) · Cytochrome P-450 CYP2C8 (1) · Cytochrome P-450 CYP3A Inhibitors (1) · Tenofovir (1)
Australia (4) · France (3) · Netherlands (3) · Hong Kong (2) · Poland (2) · South Korea (2) · United States (2) · Belgium (1) · Germany (1) · Puerto Rico (1) · Spain (1) · Taiwan (1) · Thailand (1) · United Kingdom (1)
Angela Molga, M.D. FRACP (1) · C. Voors-Pette, MD (1)
2016 (2), 2017 (1), 2018 (1), 2023 (1), 2025 (1)